AR127706A1 - Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona - Google Patents

Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Info

Publication number
AR127706A1
AR127706A1 ARP220103168A ARP220103168A AR127706A1 AR 127706 A1 AR127706 A1 AR 127706A1 AR P220103168 A ARP220103168 A AR P220103168A AR P220103168 A ARP220103168 A AR P220103168A AR 127706 A1 AR127706 A1 AR 127706A1
Authority
AR
Argentina
Prior art keywords
spiro
furo
inden
piperidin
oxazole
Prior art date
Application number
ARP220103168A
Other languages
English (en)
Inventor
Jean Adam
- Bachmann Stephan Michel
Raphael Bigler
Pascal Dott
Serena Mara Fantasia
Katja Grosse-Sender
Philippe James
Paul Spurr
Juergen Thun
Sandro Tonazzi
Paolo Tosatti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR127706A1 publication Critical patent/AR127706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona procesos para elaborar 2’-(7,7-dimetil-1’H,7H-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’H-espiro[inden-2,5’-[1,3]oxazol]-4’-ona sustituida. También se divulgan compuestos útiles como intermediarios en los métodos de la invención. Reivindicación 1: Una forma cristalina de un compuesto de fórmula (I). Reivindicación 2: La forma cristalina A del compuesto de fórmula (I) de acuerdo con la reivindicación 1, caracterizada por un patrón de difracción de rayos X de polvo que tiene los picos característicos expresados en valores de grados 2-q a aproximadamente (± 0,20 grado 2-q). @@@@@@@@@
ARP220103168A 2021-11-19 2022-11-17 Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona AR127706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21209197 2021-11-19

Publications (1)

Publication Number Publication Date
AR127706A1 true AR127706A1 (es) 2024-02-21

Family

ID=78709265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103168A AR127706A1 (es) 2021-11-19 2022-11-17 Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Country Status (4)

Country Link
CN (1) CN118251396A (es)
AR (1) AR127706A1 (es)
TW (1) TW202334162A (es)
WO (1) WO2023088996A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33001A (es) * 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
JPWO2013176220A1 (ja) 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整
SI3083633T1 (en) 2013-12-19 2018-02-28 F. Hoffmann-La Roche Ag Spiro-oxazolones

Also Published As

Publication number Publication date
TW202334162A (zh) 2023-09-01
WO2023088996A1 (en) 2023-05-25
CN118251396A (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
MD3464285T2 (ro) Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei
CO2019008868A2 (es) Derivados de pirrolo[1,2-b]piridazina
CL2012000953A1 (es) Procedimientos de preparacion de derivados espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-onas.
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PH12015501934B1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
ES2618939T3 (es) Sal de camsilato
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
PE20210002A1 (es) Sales de derivados de pirrolotriazina utiles como inhibidores tam
AR047088A1 (es) Polimorfo cristalino de piridinetilennaftofurano como antagonista del receptor de trombina, metodo de obtencion y composiciones farmaceuticas
CU24402B1 (es) 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
PE20050769A1 (es) Formas polimorficas de un agonista de gabaa
CR20110427A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
AR050536A1 (es) Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden
ECSP099441A (es) Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
PE20221340A1 (es) Compuestos heterociclicos
AR088246A1 (es) Derivados de etinilo
CO6241119A2 (es) Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
ECSP11010744A (es) PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA
AR105091A1 (es) Procedimiento para la síntesis de derivados de rapamicina
AR127706A1 (es) Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CL2021000454A1 (es) Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina
MA41802B1 (fr) Fabrication de 4,5,6,7-tétrahydroisozaxolo[5,4-c]pyridine-3-ol

Legal Events

Date Code Title Description
FB Suspension of granting procedure